Synthesis, antimycobacterial, antiviral, antimicrobial activity and QSAR studies of N(2)-acyl isonicotinic acid hydrazide derivatives. 2013

Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India

A series of N(2)-acyl isonicotinic acid hydrazides (1-17) was synthesized and tested for its in vitro antimycobacterial activity against Mycobacterium tuberculosis and the results indicated that the compound, isonicotinic acid N'- tetradecanoyl-hydrazide (12) was more active than the reference compound isoniazid. The results of antimicrobial activity of the synthesized compounds against S. aureus, B. subtilis, E. coli, C. albicans and A. niger indicated that compounds with dichloro, hydroxyl, tri-iodo and N(2)-tetradecanoyl substituent were the most active ones. The antiviral activity studies depicted that none of the tested compounds were active against DNA or RNA viruses. The multi-target QSAR model was found to be effective in describing the antimicrobial activity of N(2)-acyl isonicotinic acid hydrazides.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
March 2007, Bioorganic & medicinal chemistry letters,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
April 2014, Drug research,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
May 2014, Drug research,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
October 1957, Kekkaku : [Tuberculosis],
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
February 2014, Drug research,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
September 2003, Farmaco (Societa chimica italiana : 1989),
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
August 2001, Farmaco (Societa chimica italiana : 1989),
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
January 2016, Acta poloniae pharmaceutica,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
January 2008, Bioorganic & medicinal chemistry letters,
Vikramjeet Judge, and Balasubramanian Narasimhan, and Munish Ahuja, and Dharmarajan Sriram, and Perumal Yogeeswari, and Erik De Clercq, and Christophe Pannecouque, and Jan Balzarini
January 2020, Current drug discovery technologies,
Copied contents to your clipboard!